News articles about RestorGenex Corp. (NASDAQ:DFFN) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. RestorGenex Corp. earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.7949178619786 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

RestorGenex Corp. (NASDAQ DFFN) opened at 1.62 on Tuesday. The firm has a 50-day moving average price of $2.01 and a 200 day moving average price of $2.86. The firm’s market cap is $16.76 million. RestorGenex Corp. has a 12-month low of $1.54 and a 12-month high of $26.00.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at

RestorGenex Corp. Company Profile

Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.

Receive News & Ratings for RestorGenex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RestorGenex Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.